KDM6B and Nephropathy: Pharmacological inhibition of the HDMs involved (KDM4C and JMJD3) could be useful for abrogating the pathological consequences triggered by maladaptive UPR activation during renal damage, though in vivo studies in mouse models of kidney damage are required to further validate these results and the overall consequences in the kidney.